Jessica Serra | Head-Investor Relations and ESG |
Mark Foley | Chief Executive Officer |
Dustin Sjuts | President |
Toby Schilke | Chief Financial Officer |
Ken Cacciatore | Cowen and Co |
Seamus Fernandez | Guggenheim |
David Amsellem | Piper Sander |
Annabel Samimy | Stifel |
Balaji Prasad | Barclays |
Vamil Divan | Mizuho Securities |
Douglas Tsao | H.C. Wainwright |
Rohit Bhasin | Needham |
Welcome to the Revance Therapeutics’ First Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, May 10, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance.